Editorial: Antibody-drug conjugates in solid and hematologic malignancies.
作者信息
Saleh Khalil, Raman Ayush, Zanoni Michele
机构信息
International Department, Gustave Roussy Cancer Campus, Villejuif, France.
National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.
出版信息
Front Immunol. 2025 Aug 14;16:1662653. doi: 10.3389/fimmu.2025.1662653. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Antibody-drug conjugates in solid and hematologic malignancies.
Front Immunol. 2025 Aug 14;16:1662653. doi: 10.3389/fimmu.2025.1662653. eCollection 2025.
2
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Pharmaceutics. 2023 Aug 19;15(8):2160. doi: 10.3390/pharmaceutics15082160.
3
Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
Jpn J Clin Oncol. 2024 Aug 14;54(8):837-846. doi: 10.1093/jjco/hyae054.
4
Integrated strategy for biotransformation of antibody-drug conjugates and multidimensional interpretation via high-resolution mass spectrometry.
Drug Metab Dispos. 2025 Jun;53(6):100081. doi: 10.1016/j.dmd.2025.100081. Epub 2025 Apr 22.
5
Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs.
Mol Cancer Ther. 2025 Sep 2;24(9):1295-1307. doi: 10.1158/1535-7163.MCT-24-1182.
6
Update of antibody-drug conjugates for hematological malignancies.
Curr Opin Oncol. 2024 Sep 1;36(5):430-436. doi: 10.1097/CCO.0000000000001065. Epub 2024 Jun 28.
7
A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs.
Pharmaceutics. 2025 Jul 25;17(8):967. doi: 10.3390/pharmaceutics17080967.
8
Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention.
Int Rev Immunol. 2025 Aug 19:1-23. doi: 10.1080/08830185.2025.2545364.
9
Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms.
Biomed Pharmacother. 2025 Aug 29;191:118517. doi: 10.1016/j.biopha.2025.118517.
10
Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.
Oncol Res Treat. 2024;47(1-2):18-41. doi: 10.1159/000535491. Epub 2023 Nov 28.
本文引用的文献
1
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.
J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3.
2
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
Ann Oncol. 2025 May;36(5):561-571. doi: 10.1016/j.annonc.2025.01.011. Epub 2025 Feb 11.
3
Update of antibody-drug conjugates for hematological malignancies.
Curr Opin Oncol. 2024 Sep 1;36(5):430-436. doi: 10.1097/CCO.0000000000001065. Epub 2024 Jun 28.
4
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
5
Antibody-drug conjugates for urothelial carcinoma.
Urol Oncol. 2023 Oct;41(10):420-428. doi: 10.1016/j.urolonc.2023.06.006. Epub 2023 Jul 6.
6
Antibody-Drug Conjugates in Gynecologic Cancer.
Am Soc Clin Oncol Educ Book. 2023 May;43:e390772. doi: 10.1200/EDBK_390772.
7
Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Arch Pharm Res. 2023 Mar;46(3):131-148. doi: 10.1007/s12272-023-01433-6. Epub 2023 Mar 6.
8
The therapeutic window of antibody drug conjugates: A dogma in need of revision.
Cancer Cell. 2022 Nov 14;40(11):1255-1263. doi: 10.1016/j.ccell.2022.09.016. Epub 2022 Oct 13.
9
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Expert Opin Ther Targets. 2022 Jul;26(7):593-602. doi: 10.1080/14728222.2022.2113513. Epub 2022 Aug 19.
Zotero 插件